Clinical impact of ERG and PTEN status in prostate cancer patients underwent radical prostatectomy
https://doi.org/10.4081/aiua.2022.4.390
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Objectives: Phosphate and tensin homolog gene (PTEN) acts as a regulator of PI3-KAkt molecular pathway. ETS Related gene (ERG), an oncogene located in chromosome 21q22.2, is involved in prostate cancer (PCa) by serine 2 (TMPRSS2), a protein encoded by TMPRSS2 gene. The aim of this study is to evaluate the clinical impact of PTEN loss and ERG rearrangement in terms of oncologic results in patients diagnosed with localized PCa who underwent radical prostatectomy.
Materials and methods: Prospective data were collected from a total of 74 patients who underwent open radical retropubic prostatectomy for localized PCa and immunohistochemical study was performed in tissue samples. The primary antibodies for anti-ERG antibody as well as anti-PTEN antibody were obtained from DAKO. ERG was considered positive if at least 20% of the evaluated cells were stained at least with medium intensity. PTEN protein loss was considered when the intensity of cytoplasmic and nuclear staining was mild or entirely negative across > 10% of tumor cells.
Results: Homogenous loss of PTEN was associated with higher clinical International Society of Urological Pathology (ISUP) grade (p = 0.018) while no statistical significant association was present regarding the presence of ERG rearrangement with either ISUPc or ISUPp. After a median follow up of 34 months, 24 patients developed biochemical recurrence. No statistical significant correlation of ERG status with biochemical recurrence was noted while PTEN was associated with biochemical recurrence development in a statistical significant way. Lastly the combination of PTEN loss with ERG rearrangement presence was detected more often in higher ISUPc and ISUPp as well as biochemical recurrence development, although in a non statistical significant way.
Conclusions: Homogenous and heterogenous PTEN loss was associated with biochemical recurrence. No association of ERG and biochemical recurrence was noted. The combination of PTEN loss and ERG rearrangement presented a trend for higher ISUPc and ISUPp as well as biochemical recurrence but not in a statistical significant way.
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020 Jan;77(1):38-52
Hoag J, Barbieri C. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl 2016 Jul-Aug; 18(4): 543–548.
De Velasco MA, Uemura H. Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol. 2012;2012:419348.
Hopkins BD, Parsons RE. Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy. Clin Cancer Res. 2014 Nov 1;20(21):5379-83.
Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010 Jul;12(7):590-8.
Van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011 Aug;24(8):1128-38.
Demichelis F, Rubin M. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 2007, 26.31: 4596-4599.
Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008 Dec;21(12):1451-60.
Cooperberg MR, Pasta DJ, Elkin EP, et aL. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005 Jun;173(6):1938-42.
Phin S, Moore MW, Cotter PD. Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol. 2013 Sep 17;3:240.
Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999 Mar 19;96(6):857-68.
Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603.
Navarro D, Luzardo OP, Fernández L, Chesa N, Díaz-Chico BN. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201.
Papatsoris AG, Karamouzis MV, Papavassiliou AG. The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther. 2007 Mar;6(3):811-9.
Jamaspishvili T., Berman D.M., Ross A.E., Scher, et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology. 2018;15(4):222-234.
Dong JT, Li CL, Sipe TW, Frierson HF Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 2001;7:304–8.
Patel DM, Varma PK, Kazi MM, Patel PS, Trivedi PJ. Assessment of PTEN Gene Loss as a Possible Prognostic Marker for Prostate Cancer. J Assoc Genet Technol. 2022;48(2):63-67.
Gao T, Mei Y, Sun H, Nie Z, Liu X, Wang S. The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis. Biomed Pharmacother. 2016 Oct;83:114-121.
Troyer DA, Jamaspishvili T, Wei W, et al. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015 Aug 1;75(11):1206-15.
Jamaspishvili T, Patel PG, Niu Y, et al. Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). J Natl Cancer Inst. 2020 Nov 1;112(11):1098-1104.
Mehra R, Salami SS, Lonigro R, et al. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Med Oncol. 2018 Oct 5;35(12):152.
Xie H, Xie B, Liu C, Wang J, Xu Y. Association of PTEN expression with biochemical recurrence in prostate cancer: results based on previous reports. Onco Targets Ther. 2017 Oct 24;10:5089-5097.
Geybels MS, Fang M, Wright JL, et al. PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Oncotarget. 2017 Sep 15;8(48):84338-84348.
Lotan TL, Wei W, Morais CL, et al. PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. Eur Urol Focus. 2016 Jun;2(2):180-188.
Switlyk MD, Salberg UB, Geier OM, et al. PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings. AJR Am J Roentgenol. 2019 Mar 19:1-9.
Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509.
Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12:590–8.
Krstanoski Z, Vokac NK, Zagorac A, et al. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer. BMC Urol. 2016 Jul 4;16(1):35.
Fisher KW, Zhang S, Wang M, et al. TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. Mol Carcinog. 2017 Mar;56(3):814-820.
Kidd SG, Bogaard M, Carm KT, et al. In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis. Mol Oncol. 2022 Aug;16(15):2810-2822.
Yılmaz Ö, Berber U, Okçelik S, Soydan H, Ateş F, Karademir K. TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens. Turk J Urol. 2016 Jun;42(2):60-3.
Lee SR, Choi YD, Cho NH. Association between pathologic factors and ERG expression in prostate cancer: finding pivotal networking. J Cancer Res Clin Oncol. 2018 Sep;144(9):1665-1683.
Baohong J, Sedarsky J, Srivastava S, Sesterhenn I, Dobi A, Quanlin L. ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men. J Cancer. 2019 May 12;10(9):1991-1996.
Kong DP, Chen R, Zhang CL, et al. Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review. Asian J Androl. 2020 Mar-Apr;22(2):200-207.
Liu R, Zhou J, Xia S, Li T. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2020 May;22(5):694-702.
Khosh Kish E, Choudhry M, Gamallat Y, Buharideen SM, D D, Bismar TA. The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer. Int J Mol Sci. 2022 Apr 26;23(9):4772.
Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011 Oct 15;17(20):6563-73.
Lotan TL, Heumann A, Rico SD, et al. PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget. 2017 Jul 10;8(39):65566-65576.
Lotan TL, Wei W, Ludkovski O, et al. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol. 2016 Aug;29(8):904-14.
Navaei AH, Walter BA, Moreno V, Pack SD, Pinto P, Merino MJ. Correlation between ERG Fusion Protein and Androgen Receptor Expression by Immunohistochemistry in Prostate, Possible Role in Diagnosis and Therapy. J Cancer. 2017 Aug 5;8(13):2604-2613.
Squire JA. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet. 2009 May;41(5):509-10.
Brady L, Carlsson J, Baird AM, et al. Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. Cancer Treat Res Commun. 2021;29:100451.
Bismar TA, Hegazy S, Feng Z, et al. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. J Cancer Res Clin Oncol. 2018 Nov;144(11):2117-2125.
Hernández S, Font-Tello A, Juanpere N, et al. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Prostate. 2016 Jun;76(9):854-65.
Lahdensuo K, Erickson A, Saarinen I, et al. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. Mod Pathol. 2016 Dec;29(12):1565-1574.
Ullman D, Dorn D, Rais-Bahrami S, Gordetsky J. Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer. Urology. 2018 Mar;113:59-70.
Fragkoulis C, Glykas I, Dellis A, Ntoumas K, Papatsoris A. Clinical impact of combined PTEN and ERG rearrangements in localized prostate cancer. Arch Ital Urol Androl. 2021 Mar 19;93(1):84-85
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
